The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction.
REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]).
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial).
Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES.
Long-term statin persistence is poor among high-risk patients with baseline diabetes: a real-world administrative claims analysis
Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trial
Prevalence and predictors of residual hypertriglyceridemia according to statin use in U.S. adults with diabetes
Prevalence Of Hypertriglyceridaemia In Statin Treated Very High-Risk Patients Who Might Benefit From Treatment With Icosapent Ethyl For Secondary Prevention In Clinical Practice–Results Of DYSIS.
Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides
Increased residual cardiovascular risk in patients with diabetes and high vs. normal triglycerides despite statin-controlled LDL cholesterol
Eicosapentaenoic acid as a potential therapeutic approach to reduce cardiovascular risk in patients with end-stage renal disease on hemodialysis: a review
Retrospective case series of patients with diabetes or prediabetes who were switched from omega-3-acid ethyl esters to icosapent ethyl
Benefits of icosapent ethyl across a range of baseline renal function in patients with established cardiovascular disease or diabetes: results of REDUCE-IT RENAL [abstract FR-OR18].
Increased residual cardiovascular risk in US veterans with moderately elevated baseline triglycerides, well-controlled LDL cholesterol levels on statins, and decreased renal function [abstract PO2067].
Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl: insights from REDUCE-IT REVASC.
Substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES [abstract 627].
Lipid effects of icosapent ethyl in women with diabetes mellitus and persistent high triglycerides on statin treatment: ANCHOR trial subanalysis
Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study